Blood vessel formation (angiogenesis) is an important pathologic process in solid tumors. The liberation of vast amounts of vasoendothelial growth factor (VEGF), which attracts endothelial cells, is responsible for angiogenesis. Continue reading
Tag Archives: ramucirumab
Lilly’s Ramucirumab (anti-VEGF-2 receptor MAb) does not meet overall survival endpoint in Phase III liver cancer study
Ramucirumab, a monoclonal antibody that targets the VEGF2 (Vascular Endothelial Factor – 2) receptor failed to meet its Overall Survival endpoint in Phase III clinical study in patients with liver cancer… Continue reading